OTC · CIK 0001022899
PTIX Protagenic Therapeutics, Inc.\new
Insider trading from SEC Form 4. Last filing Aug 24, 2026. Close $0.77 on Oct 9, 2026, +502% from the 52-week low and -78% from the high.
In brief
Protagenic Therapeutics, Inc.\new (PTIX) has 14 SEC Form 4 filings on file from 6 insiders, the latest filed on Aug 24, 2026. In the last 90 days insiders made 7 open-market buys worth $31k and 0 open-market sells worth $0, net +$31k.
8 open-market trades have been scored at PTIX. The newest: Garo H Armen (EXEC. CHAIR & PRINCIPAL OFF) bought $13k of stock on Aug 21, 2026, filed Aug 24, 2026, scored 31 (weak).
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Protagenic Therapeutics, Inc.\new, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 31Weak | Garo H Armen EXEC. CHAIR & PRINCIPAL OFF buy | $13k 20,000 shares | +37% | - | |
| 28Weak | Garo H Armen EXEC. CHAIR & PRINCIPAL OFF buy | $945 2,700 shares | +8% | - | |
| 31Weak | Garo H Armen EXEC. CHAIR & PRINCIPAL OFF buy | $9,811 16,634 shares | +45% | - | |
| 28Weak | Garo H Armen EXEC. CHAIR & PRINCIPAL OFF buy | $710 2,220 shares | +7% | - | |
| 25Weak | Garo H Armen EXEC. CHAIR & PRINCIPAL OFF buy | $151 685 shares | +2% | - | |
| 28Weak | Garo H Armen EXEC. CHAIR & PRINCIPAL OFF buy | $1,294 5,000 shares | +19% | - | |
| 28Weak | Garo H Armen EXEC. CHAIR & PRINCIPAL OFF. buy | $4,806 26,291 shares | - | - | |
| 46Moderate | Alexander K. Arrow Chief Financial Officer buy | $6,480 8,000 shares | +21% | 0% from low-72% from high |
Transactions
Every row filed, 14 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 21, 2026 | Garo H Armen EXEC. CHAIR & PRINCIPAL OFF | POpen-market purchase COMMON STOCK | +20,000 | $0.65 | $13k | 73,533 | Aug 24, 2026 |
| Aug 20, 2026 | Garo H Armen EXEC. CHAIR & PRINCIPAL OFF | POpen-market purchase COMMON STOCK | +16,634 | $0.59 | $9,811 | 53,533 | Aug 20, 2026 |
| Aug 19, 2026 | Garo H Armen EXEC. CHAIR & PRINCIPAL OFF | POpen-market purchase COMMON STOCK | +2,700 | $0.35 | $945 | 36,899 | Aug 20, 2026 |
| Aug 11, 2026 | Garo H Armen EXEC. CHAIR & PRINCIPAL OFF | POpen-market purchase COMMON STOCK | +2,220 | $0.32 | $710 | 34,199 | Aug 12, 2026 |
| Aug 6, 2026 | Garo H Armen EXEC. CHAIR & PRINCIPAL OFF | POpen-market purchase COMMON STOCK | +685 | $0.22 | $151 | 31,979 | Aug 10, 2026 |
| Aug 5, 2026 | Garo H Armen EXEC. CHAIR & PRINCIPAL OFF | POpen-market purchase COMMON STOCK | +5,000 | $0.26 | $1,294 | 31,294 | Aug 6, 2026 |
| Jul 30, 2026 | Garo H Armen EXEC. CHAIR & PRINCIPAL OFF. | POpen-market purchase COMMON STOCK | +26,291 | $0.18 | $4,806 | 26,291 | Aug 3, 2026 |
| Mar 25, 2024 | Garo H Armen Executive Chairman | AGrant or award PTIX Common stock Optionsderivative | +250,000 | $1.74 | $435k | 250,000 | Mar 29, 2024 |
| Mar 25, 2024 | Alexander K. Arrow Chief Financial Officer | AGrant or award PTIX Common stock Optionsderivative | +100,000 | $1.74 | $174k | 100,000 | Mar 29, 2024 |
| Mar 25, 2024 | Khalil Barrage director | AGrant or award PTIX Common stock Optionsderivative | +22,500 | $1.74 | $39k | 22,500 | Mar 29, 2024 |
| Mar 25, 2024 | Jennifer Buell director | AGrant or award PTIX Common stock Optionsderivative | +75,000 | $1.74 | $131k | 75,000 | Mar 29, 2024 |
| Mar 25, 2024 | Brian Corvese director | AGrant or award PTIX Common stock Optionsderivative | +43,750 | $1.74 | $76k | 43,750 | Mar 29, 2024 |
| Mar 25, 2024 | Robert Benjamin Stein director | AGrant or award PTIX Common stock Optionsderivative | +75,000 | $1.74 | $131k | 75,000 | Mar 29, 2024 |
| Oct 12, 2023 | Alexander K. Arrow Chief Financial Officer | POpen-market purchase PTIX Common Stock | +8,000 | $0.81 | $6,480 | 45,815 | Oct 13, 2023 |
Insiders
Everyone who has filed a Form 4 here.
- Garo H ArmenExecutive Chairman
- Alexander K. ArrowChief Financial Officer
- Khalil Barragedirector
- Jennifer Buellchair, officer, director, ceo
- Brian Corvesedirector
- Robert Benjamin Steindirector
Questions about PTIX
Answered from the filings on this page, as of the latest one.
Are insiders buying PTIX?
As of Aug 24, 2026, SEC Form 4 filings show 7 open-market buys worth $31k by 1 insider and 0 open-market sells worth $0 by 0 insiders at Protagenic Therapeutics, Inc.\new in the last 90 days, net +$31k. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade PTIX on the open market?
Garo H Armen (EXEC. CHAIR & PRINCIPAL OFF) bought $13k of PTIX on Aug 21, 2026 and filed the Form 4 on Aug 24, 2026. InsiderTell scored 31 (weak).
How many insiders file Form 4 at Protagenic Therapeutics, Inc.\new?
6 people have filed a Form 4 at Protagenic Therapeutics, Inc.\new, among them Garo H Armen (Executive Chairman), Alexander K. Arrow (Chief Financial Officer), Khalil Barrage (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.